Aid in the detection of latent disease among persons at increased risk for tuberculosis (TB). Positive predictive value is less in low-risk populations. May be used in persons who have received BCG vaccine.
Orderable SIM Number(s)
QUANTIFERON TB GOLD (LAB10118)
Synonyms
Quantiferon-TB Gold in Tube
Interferon-Gamma Release Assay for Tuberculosis
Latent Tuberculosis Infection (LTBI)
QFT & M TB
QFT-G & M.tuberculosis
QFT-TB
Quantiferon Mitogen and NIL
QuantiFERON-TB Gold In Tube & Mycobacterium tuberculosis Antibody
QuantiFERON-TB Gold Plus, 4-Tube
LAB10118
Q-Gold Test
Collect
QuantiFERON-TB Gold Plus (Standard) 4-Tube Collection Kit (Lawson #622433). Contact Aspirus Reference Laboratory (ARL) for collection kit. These are not the same tube types used for standard blood draws.
Collection Instructions:
Follow the order of draw: gray, green, yellow, purple.
If drawing with needle, leave the tubes on the needle for 2-3 seconds once the tube appears to have completed filling.
Recommendation is to draw with a syringe and 1 mL transferred to each of the tubes.
If drawing with butterfly, a “purge” tube should be used to ensure that the tubing is filled prior to the Q-gold tubes.
Fill to between black marks on each tube label (1mL of blood). DO NOT UNDER or OVER- FILL.
Specimen Preparation
Label each tube with two patient identifiers and transport blood in the original containers. (1 mL per container)
Storage/Transport Temperature
Samples MUST be delivered to the Aspirus Reference Laboratory within 16 hours of collection atRoom Temperature (Ambient).
Processing Exception - For a select few hospital laboratory submitting locations only when necessary due to travel time limitations:
Samples are incubated for 16 to 24 hours at 37 degrees C and then spun for 15 minutes at 2000-3000 RCF (g).
Samples must be sent to ARL refrigerated.
***Indicate that samples have been incubated and spun***
Interferon gamma release is measured for specimens from each of the four collection tubes. A qualitative result (Negative, Positive, or Equivocal) is based on interpretation of the four values, NIL, MITOGEN minus NIL (MITOGEN-NIL), TB1 minus NIL (TB1-NIL), and TB2 minus NIL (TB2-NIL). The NIL value represents nonspecific reactivity produced by the patient specimen. The MITOGEN-NIL value serves as the positive control for the patient specimen, demonstrating successful lymphocyte activity. The TB1-NIL tube specifically detects CD4+ lymphocyte reactivity, specifically stimulated by the TB1 antigens. The TB2-NIL tube detects both CD4+ and CD8+ lymphocyte reactivity, stimulated by TB2 antigens. An overall Negative result does not completely rule out TB infection.
A false-positive result in the absence of other clinical evidence of TB infection is not uncommon. Refer to: Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis Infection --- United States, 2010 http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5905a1.htm, for more information concerning test performance in low-prevalence populations and use in occupational screening.
CPT Codes
86480
Billable SIM Number(s)
3028648001
LOINC
71776-9
74774-4
64084-7
88517-8
71773-6
Overview
Ordering Recommendations
Aid in the detection of latent disease among persons at increased risk for tuberculosis (TB). Positive predictive value is less in low-risk populations. May be used in persons who have received BCG vaccine.
Orderable SIM Number(s)
QUANTIFERON TB GOLD (LAB10118)
Synonyms
Quantiferon-TB Gold in Tube
Interferon-Gamma Release Assay for Tuberculosis
Latent Tuberculosis Infection (LTBI)
QFT & M TB
QFT-G & M.tuberculosis
QFT-TB
Quantiferon Mitogen and NIL
QuantiFERON-TB Gold In Tube & Mycobacterium tuberculosis Antibody
QuantiFERON-TB Gold Plus, 4-Tube
LAB10118
Q-Gold Test
Specimen
Collect
QuantiFERON-TB Gold Plus (Standard) 4-Tube Collection Kit (Lawson #622433). Contact Aspirus Reference Laboratory (ARL) for collection kit. These are not the same tube types used for standard blood draws.
Collection Instructions:
Follow the order of draw: gray, green, yellow, purple.
If drawing with needle, leave the tubes on the needle for 2-3 seconds once the tube appears to have completed filling.
Recommendation is to draw with a syringe and 1 mL transferred to each of the tubes.
If drawing with butterfly, a “purge” tube should be used to ensure that the tubing is filled prior to the Q-gold tubes.
Fill to between black marks on each tube label (1mL of blood). DO NOT UNDER or OVER- FILL.
Specimen Preparation
Label each tube with two patient identifiers and transport blood in the original containers. (1 mL per container)
Storage/Transport Temperature
Samples MUST be delivered to the Aspirus Reference Laboratory within 16 hours of collection atRoom Temperature (Ambient).
Processing Exception - For a select few hospital laboratory submitting locations only when necessary due to travel time limitations:
Samples are incubated for 16 to 24 hours at 37 degrees C and then spun for 15 minutes at 2000-3000 RCF (g).
Samples must be sent to ARL refrigerated.
***Indicate that samples have been incubated and spun***
Interferon gamma release is measured for specimens from each of the four collection tubes. A qualitative result (Negative, Positive, or Equivocal) is based on interpretation of the four values, NIL, MITOGEN minus NIL (MITOGEN-NIL), TB1 minus NIL (TB1-NIL), and TB2 minus NIL (TB2-NIL). The NIL value represents nonspecific reactivity produced by the patient specimen. The MITOGEN-NIL value serves as the positive control for the patient specimen, demonstrating successful lymphocyte activity. The TB1-NIL tube specifically detects CD4+ lymphocyte reactivity, specifically stimulated by the TB1 antigens. The TB2-NIL tube detects both CD4+ and CD8+ lymphocyte reactivity, stimulated by TB2 antigens. An overall Negative result does not completely rule out TB infection.
A false-positive result in the absence of other clinical evidence of TB infection is not uncommon. Refer to: Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis Infection --- United States, 2010 http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5905a1.htm, for more information concerning test performance in low-prevalence populations and use in occupational screening.
